198 related articles for article (PubMed ID: 28090017)
1. [Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma].
Hatsuse M; Odaira E; Fuchida SI; Okano A; Murakami S; Shimazaki C
Rinsho Ketsueki; 2016; 57(12):2502-2506. PubMed ID: 28090017
[TBL] [Abstract][Full Text] [Related]
2. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Thornburg A; Abonour R; Smith P; Knox K; Twigg HL
Chest; 2007 May; 131(5):1572-4. PubMed ID: 17494808
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide-induced hypersensitivity pneumonitis.
Kortuem M; Einsele H
Onkologie; 2010; 33(5):219. PubMed ID: 20502054
[No Abstract] [Full Text] [Related]
5. [Interstitial pneumonitis as an adverse effect of thalidomide].
Scholte JB; Potjewijd J; Voogt PJ; Custers FL; Jie KS
Ned Tijdschr Geneeskd; 2009; 153():A452. PubMed ID: 20051154
[TBL] [Abstract][Full Text] [Related]
6. [A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Kuroda H; Yoshida M; Usami M; Shimoyama S; Sakamoto H; Yamada M; Fujii S; Maeda M; Fujita M; Kanari Y; Sato T; Kato J
Gan To Kagaku Ryoho; 2015 Aug; 42(8):1009-12. PubMed ID: 26321720
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
[TBL] [Abstract][Full Text] [Related]
8. [A case of tuberculous pleurisy associated with myoclonus and Quincke's edema due to isoniazid and isoniazid sodium methanesulfonate].
Yagi S; Moriya O; Nakajima M; Umeki S; Hino J; Soejima R
Kekkaku; 1989 Jun; 64(6):407-12. PubMed ID: 2796112
[TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity pneumonitis associated with the use of temozolomide.
Koschel D; Handzhiev S; Leucht V; Holotiuk O; Fisseler-Eckhoff A; Höffken G
Eur Respir J; 2009 Apr; 33(4):931-4. PubMed ID: 19336595
[TBL] [Abstract][Full Text] [Related]
11. [Desensitization to lenalidomide].
Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
[No Abstract] [Full Text] [Related]
12. [Case of thalidomide-induced interstitial pneumonia].
Matsushima H; Oda T; Yamamoto M; Sato A; Hasejima N; Takezawa S
Nihon Kokyuki Gakkai Zasshi; 2009 May; 47(5):438-42. PubMed ID: 19514509
[TBL] [Abstract][Full Text] [Related]
13. [Interstitial pneumonitis as an adverse effect of thalidomide].
Scholte JB; Potjewijd J; Voogt PJ; Custers FL; Lie KS
Ned Tijdschr Geneeskd; 2009; 153():A452. PubMed ID: 19785872
[TBL] [Abstract][Full Text] [Related]
14. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Kuroda J; Kobayashi T; Taniwaki M
Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
[TBL] [Abstract][Full Text] [Related]
16. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Paumgartten FJ
Cad Saude Publica; 2014 Apr; 30(4):684-6. PubMed ID: 24896044
[No Abstract] [Full Text] [Related]
18. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
[TBL] [Abstract][Full Text] [Related]
19. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
Uchida T; Inoue M; Hua J; Hagihara M
Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
